The Role of Biological Therapies in the Management of Systemic Vasculitis by Paloma Vela & Mariano Andrés
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
7 
The Role of Biological Therapies in the 
Management of Systemic Vasculitis 
Paloma Vela and Mariano Andrés 
Sección de Reumatología, Hospital General Universitario de Alicante 
Spain 
1. Introduction 
Systemic vasculitides are multisystem disorders with an autoimmune basis leading to blood 
vessel inflammation. Vasculitis present a wide spectrum, being classified regarding different 
aspects on pathogenesis, histopathology or laboratory findings. The most common used 
classification considers size of the vessel predominantly affected, established at Chapel Hill 
Consensus Conference (Jennete et al, 1994): large-sized vessels (giant-cell arteritis, 
Takayasu’s arteritis), medium-sized vessels (polyarteritis nodosa, Kawasaki’s disease) and 
small-sized vessels (Wegener granulomatosis, microscopic polyangiitis, Churg-Strauss 
syndrome, cryoglobulinemia, Henoch-Schönlein purpura, and cutaneous leukocytoclastic 
angiitis). Behçet’s disease affects small and large vessels of the arterial and venous systems. 
Systemic vasculitis predominantly associated with the presence of serum anti-neutrophil 
cytoplasmic antibodies (ANCA) are known as ANCA-associated vasculitis, in spite of about 
10-20% of this vasculitis present with classical clinical picture but ANCA negative. 
Systemic vasculitis are rare diseases with wide and heterogenic range of manifestations, so 
leading prospective controlled clinical trials in pathogenesis and management of these 
diseases is difficult. Despite these limitations, first descriptions about vasculitis in mid-20th 
century ascertained that some forms of vasculitis are severe and potentially fatal in a short-
term period (weeks-months) with no treatment. These are mainly Wegener disease and 
microscopic polyangiits with critical organ involvement (kidney, lung, gastrointestinal 
system or central nervous system), but they are not the only ones. Introduction of 
glucocorticoids and, later, immunosuppressive agents (cyclophosphamide, methotrexate, 
azathioprine, etc.) contributed to achieve remission of these diseases and prevent further 
organ damage, former potentially fatal. 
But nowadays many questions are still unsolved. In ANCA-associated vasculitis, high rate 
of remission (about 80-90% patients) is followed by an unacceptable rate of relapses, which 
is especially important in Wegener granulomatosis, reaching up to 50% of patients within 2 
years after the diagnosis (Hoffman et al, 1992), with further morbidity and mortality. 
Another concern is about cytotoxic regimens for induction of remission on these diseases: 
although current schemes are less toxic, severe infections and bone marrow toxicity still are 
major problems, so serious adverse events and mortality in early stages are not related to 
disease activity, but to therapy in a significant proportion of cases (Little MA et al, 2010). 
In last decade, the advent of target-defined drugs, known as biological agents, became a 
substantial advance for the management of several diseases in different medical areas, as 
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Fig. 1. Common biological agents and their targets on immune system cells and molecules. 
APC: antigen-presenting cell; GM-CSF: granulocyte-monocyte colonial stimulating factor; 
TNF: tumour necrosis factor; IL: interleukin. [Figure by Enrique Sillero MD]. 
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rheumatology, nephrology, haematology, oncology, dermatology or digestive medicine. 
They are immunological agents, monoclonal antibodies or recombinant soluble receptors, 
designed against simple targets on serum (for example, tumor necrosis factor-, interleukin-
1 or interleukin-6) or cell surface (for example, CD20, CD3 or epidermical growing factor 
receptor) (Figure 1). In autoimmune disorders, biological agents proved to be highly 
effective in rheumatoid arthritis, inflammatory bowel disease, psoriasis or autoimmune 
haemolytic anaemia, also in refractory forms. As any other agents, biological therapies carry 
some adverse events, as increased risk of infections, hypersensitivity or infusion-related 
reactions and skin disorders. An increased risk of further malignancies is not clear. But 
overall benefit-risk ratio is very high. 
In systemic vasculitis, the introduction of biological therapy in last decade has provided the 
hope of a more targeted treatment with greater efficacy, fewer side effects and longer-lasting 
remissions. They may also be a promising solution for refractory cases. In this chapter, the 
current evidence about the use of biological agents in systemic vasculitis will be reviewed. 
2. ANCA-associated vasculitis 
2.1 Introduction 
Wegener’s granulomatosis, Churg-Strauss syndrome and microscopic polyangiitis are types 
of systemic vasculitis associated to the presence of detectable serum anti-neutrophil 
cytoplasmic antibodies (ANCA). Less than 10% of cases of polyarteritis nodosa show 
positive ANCA. As previously described, ANCA vasculitis are severe conditions with a fatal 
outcome with no treatment. Former high mortality rates became lower after the introduction 
of an intensive management with immunosuppressive agents as cyclophosphamide. Despite 
this improvement, unacceptable rates of relapses and drug-related adverse events made the 
search of more effective and more safety agents highly desirable, and biological agents have 
been used and tested with this purpose. Their results will be discussed in this section. 
2.2 TNF blockade 
Anti-tumour necrosis factor (TNF) agents have been widely used in ANCA-associated 
vasculitis. TNF is a prominent cytokine involved in the formation of granuloma in 
infectious and inflammatory diseases, and many other evidence support TNF blockade in 
ANCA-associated vasculitis: TNF gene expression and cytokine production by lymphocytes 
is increased in patients with Wegener (Deguchi et al, 1990; Ludviksson et al, 1998); TNF 
soluble receptor levels seemed to correlate with disease activity (Nassonov at al, 1997) and 
TNF-positive cells predominate in inflammatory infiltrates found in renal biopsies from 
patients with ANCA vasculitis (Noronha I et al, 1993). 
Uncontrolled studies where anti-TNF drugs were used in patients with refractory ANCA 
vasculitis showed promising results in efficacy and safety. Chimeric monoclonal antibody 
infliximab was tried in six patients with refractory Wegener granulomatosis – one persistent 
and five relapsing diseases - in a preliminary study (Lamprecht et al, 2002). In different 
dosage (3mg/kg in 2 patients and 5 mg/kg in 4 patients), the addition of infliximab to 
standard therapy achieved remission in five out six patients, being discontinued in the 
remaining one due to a non-confirmed infection. In another study (Booth et al, 2004), an 
open-labelled multicenter non-controlled trial, infliximab was associated with a high rate of 
remission (88% patients in about 6 weeks) in 28 patients with Wegener granulomatosis and 
microscopic polyangiitis. Disease activity scores, inflammatory markers and prednisolone 
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doses were significantly reduced all throughout the study. These promising data with 
infliximab carried on some queries: discontinuation of the drug followed by high rate of 
relapses in a short period - about 20%patients in 16 months of follow-up; there were no 
control group; patients presented a significant rate of severe adverse events, with 2 deaths, 6 
severe infections and one malignancy. The pattern of organ involvement and detected 
microorganism were consistent with recognized events in other infliximab-treated 
disorders. 
In an exploratory study (Stone et al, 2001), fusion protein etanercept - a combination of p75 
soluble TNF receptor and Fc portion of human IgG1 – were added to standard therapy for 
patients with refractory Wegener granulomatosis, persistently active or relapsing forms. 
Twenty patients received etanercept 25mg subcutaneous twice a week for 6 months. The 
study endpoint was safety and there was no control group. After 6 months of follow up, the 
most common adverse event was related to injection site reactions, and no serious adverse 
events were detected. Though no study endpoint, good results were noted in efficacy; the 
authors found a reduction in disease activity, even remissions in 80% of patients, with 
reductions in prednisolone doses.  
These promising results in safety and efficacy led to further randomized controlled trial 
(WGET Research Group, 2005). In this multicenter, randomized, double-blind, placebo-
controlled trial, 181 patients with active Wegener disease – not other forms of ANCA 
vasculitis were included – were randomized to receive etanercept 25mg subcutaneously 
twice a week or placebo, along with standard therapy, in order to evaluate the maintenance 
of remission. Surprisingly, no significant differences were found in the rate of sustained 
remission – 69% patients in etanercept group versus 75% patients in control group – and 
results did not depend on severity or duration of the disease. But the most astonishing 
finding was related to safety: both groups presented a similar rate of severe adverse events; 
in etanercept group, however, 6 malignancies were detected, with none in placebo group. It 
is a standardised incidence rate over 300% compared to expected rate in this group 
matching per age and sex. It is noteworthy that relapsing disease, what means more 
previous exposure to immunosuppressive agents, was higher in etanercept group.  
Recently, fully humanised TNF monoclonal antibody adalimumab has been tested in 
ANCA-associated vasculitis (Laurino et al, 2010). An open-label, prospective uncontrolled 
trial was underwent to study adalimumab (40mg subcutaneously every 2 weeks) as an 
adjuvant to standard therapy in flares of Wegener granulomatosis and microscopic 
polyangiits. Results were comparable to infliximab: a high rate of remission followed by 
frequent relapses (6 out 14 patients in less than 2 years after remission) and 2 cases of severe 
infections, one fatal. 
Data about TNF blockade in other forms of necrotising systemic vasculitis are scarce. 
Churg-Strauss syndrome is often mild and controlled with glucocorticoids. But data suggest 
that small portion of patients will present a severe disease requiring intensive treatment. 
Anti-TNF agents might be an effective option for these patients (Arbach et al, 2002). 
Currently very rare after widespread hepatitis B vaccination, polyarteritis nodosa is a 
systemic necrotising vasculitis affecting medium-sized vessels and seldom associated to 
ANCA (less than 10% of cases). A case of refractory and severe polyarteritis nodosa 
successfully treated with infliximab has been reported (Al-Bishri et al, 2005). 
In summary, huge evidence about TNF blockade in ANCA-associated vasculitis is lacking. 
High rates of remission in refractory cases were found, especially in uncontrolled studies; 
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but high rate of relapses after discontinuation and intolerable severe adverse events 
(especially infections and increased risk of malignancies - found with etanercept) make anti-
TNF agents not formally recommended for the management of ANCA-associated vasculitis. 
2.3 B-cell targeted therapies 
B-lymphocytes are one of the cornerstone cells in immune system, with pleiotropic effects: 
antibody production, antigen presentation, cytokine secretion or T-lymphocytes regulation. 
As previously mentioned, systemic necrotising vasculitis are largely related to ANCA 
autoantibodies against neutrophil proteins, mainly proteinase-3 and myeloperoxidase. B-
lymphocytes are responsible of ANCA production, and plasma activated B-cell titre is 
related to disease activity (Popa et al, 1999). So B-cells are a logical target for the 
management of ANCA-associated vasculitis. 
Rituximab is a chimeric monoclonal antibody against CD20; CD20 is a surface marker found 
almost exclusively in B-lymphocytes (immature and mature cells), except of plasma cells. 
Rituximab is an effective agent for B-cell non-Hodgkin lymphoma and several autoimmune 
disorders, as rheumatoid arthritis. Several case reports and small series found rituximab as a 
potential agent for patients with refractory ANCA vasculitis (Specs et al, 2001; Omdal et al, 
2005; Stasi et al, 2006; Tektonidou & Skopouli, 2006; Tamura et al, 2007; Ferraro et al, 2008; 
Sanchez-Cano et al, 2008; Seo et al, 2008). Encouraged by previous reports, a prospective 
open-label pilot trial with rituximab in refractory Wegener granulomatosis was underwent 
(Keogh et al, 2006). In this trial, ten patients with refractory disease - three with persistent 
and seven with relapsing disease - were treated with rituximab 4 weekly infusions of 
375mg/m2, along with glucocorticoids. All of these patients achieved complete remission in 
less than 5 months after last infusion, and 9 out ten continued with remission at the end of 
the study (12months); only one patient relapsed, at 9 months. In this trial, clinical response 
appeared to be related to successful B-cell depletion. Another trial (Jones et al, 2009), larger 
(65 patient) but retrospective, supported this results: rituximab induced remission in 75% of 
patients with relapsing or persistent ANCA-associated vasculitis, in this case also including 
microscopic polyangiitis and Churg-Strauss syndrome. Relapse occurred in 57% of patients, 
but subsequent courses also achieved remission. 
These very promising data from uncontrolled studies warranted confirmation in 
randomised controlled trials. Two were recently published. RITUXVAS trial (Jones et al, 
2010) was a non-inferiority open-label trial about rituximab as an induction of remission 
agent in ANCA-associated vasculitis with renal involvement, compared to standard regime 
(cyclophosphamide and steroids). Patients in treatment group received rituximab using 
lymphoma scheme (375mg/m2 weekly 4 weeks) along with cyclophosphamide (15mg/kg 2 
i.v. pulses with the first and third rituximab infusions) and glucocorticoids. Patients with 
new Wegener disease, microscopic polyangiitis and renal-limited vasculitis were enrolled 
and randomised to each group in a 3:1 ratio. No differences in sustained remission were 
found between both groups (76% in rituximab group versus 82% in control group, p=0.68), 
time to remission was similar (about 90 days) and safety data was comparable. Fifteen 
percent of patients in rituximab group and 10% patients in control group relapsed after 12 
months of follow-up. Stone et al (2010) conducted the RAVE trial, a double-blind, 
randomised control trial where rituximab was tested as non-inferior to cyclophosphamide 
for induction of remission in ANCA-associated vasculitis. Investigators recruited patients 
with active disease, newly diagnosed or relapsed. In this trial, rituximab (lymphoma 
scheme) plus placebo was compared to daily oral cyclophosphamide plus placebo. 
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Remission rate was similar in both groups – 64% rituximab  versus 53% control – being 
noteworthy that was lower than usual remission rates, about 80-90% (Hoffman et al, 1992). 
In relapsing subgroup rituximab was superior to cyclophosphamide; a possible explanation 
might be that patients with relapsing disease were initially treated with cyclophosphamide 
and are less likely to respond to new cyclophosphamide rather than those with new-onset 
disease. Relapses were low and did not differ between groups. Safety data was again 
comparable, with more leukopenia in cyclophosphamide group.  
If B-cell repopulation or ANCA levels should guide further courses of rituximab in order to 
prevent relapse is still to be determined. In trial by Keogh et al  (2006), B-cells depleted in all 
patients after rituximab, and further ANCA levels augments (previously decreased in all 
patients) coincided or followed B-cell reconstitution; in this trial only one patient relapsed, 
preceded by B-cell repopulation and ANCA increase. But this association was not found in 
other studies (Jones et al, 2009). 
Churg-Strauss syndrome was seldom included in above studies, but successful outcome in 
refractory cases using rituximab has been reported as well (Kaushik et al, 2006; Koukoulaki 
et al, 2006; Pepper et al, 2008]. We found no data about rituximab in polyangiitis nodosa. 
In summary, B-cells are a very promising target as a part of the management of ANCA-
associated vasculitis. Presented data support the use of rituximab as an induction of 
remission agent, especially in persistent or relapsing disease. Due to randomised controlled 
trial results, rituximab should be even consider as a first-line agent, though is not licensed 
for this employ. One grey area of ANCA-associated vasculitis remains unanswered with 
rituximab: while successful results in remission have been reported, patients still present an 
unacceptable rate of relapses. RITUXVAS and RAVE trials did not explore rituximab as a 
maintenance agent, and follow-up was too short (12 and 6 months respectively) to assess it. 
Further studies are warranted and desirable. 
2.4 T-cell targeted therapies 
Along with B cells, autoreactive T lymphocytes have a major role in pathogenesis of ANCA-
associated vasculitis (Popa et al, 2002). So T-cell depletion might have a role in the 
management of these conditions. Alemtuzumab (CAMPATH-1H) is a humanised 
monoclonal antibody against CD52, present in T lymphocytes and macrophages, leading to 
T cell depletion. Tested in other immune disorders – like rheumatoid arthritis, multiple 
sclerosis or renal transplantation – alemtuzumab was used in refractory cases of ANCA-
associated vasculitis, especially Wegener disease. Walsh et al (2008) reported long-term 
results of 71 patients with refractory or relapsing disease treated with alemtuzumab. Use of 
alemtuzumab achieved high remission rates (85% of patients) but high relapsing rate as well 
(60%), and patients developed an unacceptable rate of severe adverse events, in particular 
infections. Infections are probably due to deep immune suppression by alemtuzumab, but it 
is noteworthy that several patients had other risk factors for severe infections: 23% showed 
undetectable CD4+ cells before alemtuzumab probably related to prior intensive 
immunosuppressive agents, 8% were hemodyalisis-dependent and 18% presented a life-
threatening disease requiring intensive unit care. Data with anti-thymocyte globulin, which 
also leads to lymphocyte depletion, is quite similar (Lukas & Keller, 1998; Hagen et al, 1995]. 
No further controlled trials have been undertaken. 
CTLA-4 (CD152) is a surface molecule on activated T-cell membrane. CTLA-4 binds B7.1 
(CD80) and B7.2 (CD86) from antigen-presenting cells, leading to T-cell co-stimulation. 
CTLA-4 has a role on immune regulation, mainly switching from Th2 to Th1-response 
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pattern. This effect is antagonist to CD28. Predominantly Th1 response was found in 
granulomatous inflammation (Csernok et al, 1999), CTLA-4 expression is increased in 
patients with active disease (Steiner et al, 2001) and associations with some CTLA-4 
polymorphysms were found (Huang et al, 2000; Giscombe et al, 2002; Zhou et al, 2004], all in 
Wegener granulomatosis. In this context, CTLA-4-Ig abatacept might be a potential agent in 
the management of ANCA-associated vasculitis. No case reports or series have been 
published, but results from an ongoing trial, ABAVAS (www.clinicaltrials.gov), are awaited. 
2.5 Other biological agents 
We found no other reports about other biologics in ANCA-associated vasculitis. 
Recombinant interleukin-6 receptor tocilizumab might have a role, so as interleukin-6 levels 
are increased in these disorders and correlated to disease activity (Nakahama et al, 1993). 
Conversely, no differences in interleukin-1 levels were found between patients with active 
ANCA vasculitis, convalescent vasculitis and healthy controls [Nogueira E et al, 2010], 
making anakinra and other IL-1 antagonists unlikely to be effective. 
3. Large vessel vasculitides 
The primary large vessel vasculitides, Takayasu’s arteritis (TA) and giant cell arteritis 
(GCA), are chronic inflammatory diseases of the large elastic arteries characterised by 
systemic inflammation and critical ischemia. GCA primarily affects temporal arteries and 
other extracranial branches, while in TA the aorta and its proximal branches are usually 
involved. TA predominates in young adults, but patients with GCA are usually older. 
Though these differences, some authors suggested that both entities might be two poles of 
the spectrum within the same disease (Maksimowicz-McKinnon et al, 2009). Glucocorticoids 
continue being the mainstay of initial therapy, but long-term use is associated with a great 
amount of adverse side effects. Both conditions can follow a chronic relapsing course, 
requiring long-term therapy. In addition, most patients that initially respond to 
glucocorticoids flare on dose reduction or discontinuation. In the Cleveland cohort 
(Maksimowicz-McKinnon et al., 2007), only 20% of patients persisted on remission with <10 
mg prednisolone for 6 months. It is therefore common the need of an additional 
immunosuppressive agent to induce or maintain remission in large cohorts (Kerr et al., 1994; 
Vanoli et al., 2005; Park et al., 2005).  
Granulomatous inflammation is one of the key histopathological features of large vessel 
vasculitides. Taking into account the role of tumour necrosis factor-alpha (TNF) in the 
formation and maintenance of the granuloma, it could be expected that anti-TNF therapies 
may be beneficial in refractory forms of large vessel vasculitides. TNF is a pro-
inflammatory cytokine produced primarily by cells from monocyte-macrophage lineage. Its 
biologic effects include adhesion molecule expression, synthesis of chemokines and other 
pro-inflammatory cytokines, activation of immune system cells (T-cells, B-cells and 
macrophages), and inhibition of regulatory T-cells (Chung & Seo, 2009). TNF can be found 
in both cell membrane-bound and soluble forms. At this time, five agents directed against 
TNF are approved for use in rheumatoid arthritis and other inflammatory arthropathies: 
infliximab, etanercept, adalimumab, certolizumab and golimumab.  
3.1 Takayasu´s arteritis 
TA primarily involves the aorta and its primary branches. The inflammatory process cause 
wall thickening on the affected arteries. Although experience with anti-TNF agents in 
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difficult-to-treat cases of TA is limited, multiple investigators have reported successful 
results.  
Hoffman and associates published the first long-term study of anti-TNF therapy in TA in 
2004 (Hoffmann et al., 2004). In this open-label trial, 15 patients with refractory forms of TA 
were enrolled. Thirteen of them had high doses requirements of glucocorticoids to maintain 
remission and relapsed while treated with conventional and experimental therapy; and 2 of 
them refused re-treatment with glucocorticoids following relapses (2 of the 15 patients). 
Anti-TNF agents were used, seven patients received etanercept (ETN) (25 mg twice weekly) 
and eight received infliximab (IFX) (from 3 to 5 mg/kg initially, and at two weeks, six 
weeks, and every four to eight weeks thereafter). Previous treatments included 
methotrexate, cyclophosphamide, mycophenolate, cyclosporin and tacrolimus. Rapid 
improvement was noted in 14 out 15 patients, within 2–8 weeks. Sustained remission, 
lasting 1 – 3.3 years, was achieved in 10 patients (75%) who were able to discontinue 
glucocorticoids. Four patients (27%) partially responded and were able to reduce the steroid 
dose by at least 50%. At 12 months, most patients required no steroids. One patient did not 
respond to IFX. Nine of the 14 patients with an initial response to 3 mg/kg of IFX required 
dose escalation to maintain disease control. Two relapses occurred with interruption of 
therapy, but disease control was regained when treatment was restarted. 
Molloy et al (2008) reported the largest case series to date in the literature, a retrospective 
study examining 25 patients with active, relapsing TA. Patients were treated with IFX (n=21) 
or ETN (n=9) and followed for a median of 28 months. Of the nine patients initially treated 
with ETN, four underwent complete remission and two experienced partial remission. Two 
of the four patients in complete remission switched to IFX, one due to unavailability of ETN 
(and subsequently had a sustained remission) and the other due to a major disease flare at 
67 months, but relapsed after two IFX infusions and treatment was subsequently stopped. 
Of the six patients in remission, three had disease relapses: two of them regained disease 
control with an increase in dose of ETN to 50 mg twice weekly, and the other one also 
required addition of prednisolone. Three patients who did not respond to ETN were 
switched to IFX and achieved complete remission. Of the 21 patients treated with IFX 
(including the five previously treated with ETN), 12 achieved complete remission and six 
achieved partial remission. Three patients discontinued IFX; 12 of the remaining 18 patients 
relapsed and required treatment with higher doses of IFX administered at shorter intervals. 
Median stable IFX dose was 5 mg/kg (range 4–10 mg/kg), administered at a median 
interval of 6 weekly (range 4–8 weekly). Of the nine patients that either permanently or 
temporarily discontinued IFX, eight had a disease flare at a median interval of 5 months 
(range 2–12); two of these patients restarted IFX treatment and again achieved remission.  
Other small series have reported a similar rapid response to IFX, with dose escalation 
frequently needed to maintain remission (Karageorgaki et al., 2007; Tanaka et al., 2006; Jolly 
& Curran, 2005; Della Rossa et al., 2005). Also, a further case of refractory TA entered 
remission with adalimumab when infliximab was discontinued after a lupus-like reaction 
(Tato et al., 2005). Current data may suggest that the use of IFX compared with etanercept or 
adalimumab is recommendable, but one should note that doses frequently had to be 
escalated above the baseline 3 mg/kg dose to achieve remission. 
In summary, the positive results from these case series and case reports of the use of anti-
TNF agents for refractory TA are encouraging, but an adequately powered, randomized 
controlled trial is needed to ascertain their role. 
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3.2 Giant-cell arteritis 
Giant-cell arteritis (GCA), also known as temporal arteritis, is an immune-mediated chronic 
disease characterized by granulomatous infiltrates in the wall of medium and large-sized 
arteries. Vessel wall inflammation leads to luminal occlusion and tissue ischemia. Patients 
with GCA complain of persistent unilateral headache, jaw claudication, visual disturbances, 
malaise and weight loss (Seo & Stone, 2004). As well as TA, GCA is characterized by 
granulomatous inflammation, so TNF inhibition would appear to be an appropriate 
treatment approach.  
Some small case series pointed that IFX might be useful as a steroid-sparing agent for GCA 
(Cantini et al, 2001; Andonopoulos et al, 2003; Airo et al, 2002). Based on these results, a 
randomized, multicenter trial of IFX versus placebo was conducted, but surprisingly failed 
to show efficacy (Hoffman et al, 2007). Forty-four patients newly diagnosed with GCA were 
randomly assigned in a 2:1 (IFX 5 mg/kg: placebo) ratio to receive infusions at weeks 0, 2, 
and 6, and every 8 weeks thereafter, after prednisone-induced remission. Primary outcomes 
were the number of relapse/recurrence free patients through week 22 and adverse events, 
while secondary outcomes included time to first relapse, number of relapse-free patients 
when prednisone was tapered to 10 mg day, and cumulative prednisone dose.  Sixteen 
patients were assigned to prednisone plus placebo, and 28 to prednisone plus IFX. At 22 
weeks, the proportion of patients without relapse was similar between the IFX and placebo 
groups (43 versus 50% respectively, P=0.65). In addition, IFX did not increase the proportion 
of patients whose prednisone dose could be tapered to 10 mg/d without relapse (61% for 
IFX versus 75% for placebo, P=0.31). There was a trend for more infections in the IFX (71%) 
than in the placebo (56%) group. Consequently, the trial was stopped early. The 
investigators concluded that the addition of IFX to glucocorticoids neither improve the 
durability of remissions nor reduce cumulative glucocorticoids requirements in GCA. This 
data suggests that, similarly to what has been reported in PMR (Salvarani et al., 2007), TNF 
inhibition is effective to some extent in long-standing, refractory GCA, but not (or only 
marginally) effective in new-onset GCA. The results of these studies led the European 
Vasculitis Study (EUVAS) group to not recommend the use of infliximab in GCA as an 
adjuvant therapy to glucocorticoids (Mukhtyar et al, 2009). 
The first randomized trial showed etanercept as a useful steroid-sparing agent in refractory 
GCA (Martinez-Taboada et al, 2008). Fifteen patients with biopsy-proven GCA, in remission 
with a stable dose of prednisone (median 15 mg daily) were included. Prednisone was 
tapered according to a predefined schedule allowing for dose adjustments in case of flares. 
Placebo or etanercept 25 mg were given subcutaneously twice weekly for 12 months 
followed by a 3-month observation period. Patients in the etanercept group discontinued 
more easily prednisone (although the difference did not reach significance) and the 
cumulative dose after 12 months of treatment was significantly lower. The number and 
severity of adverse events was similar in both groups. The results of this study thus appear 
to support the concept that TNF blockade with etanercept has a clinically relevant effect in 
suppressing disease activity in refractory GCA (Salvarani et al, 2008). It should be 
mentioned however that treatment arm only contained eight patients. 
Interleukin-6 blockade with tocilizumab (a humanized anti-interleukin-6 receptor 
monoclonal antibody) seems to be a promising target for future randomized controlled 
trials; current reported uses are limited (Seitz et al, 2011). Other possible therapeutic agents 
include abatacept, a recombinant fusion protein that modulates CD28-mediated T-cell co-
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stimulation, and rituximab, a B-cell depleting antibody. The last has been used in one 
patient with GCA, with resolution of arteritis at 4.5 months (Bhatia et al, 2005). However, 
this patient subsequently developed pneumonia that required mechanical ventilation. 
4. Behçet’s disease 
4.1 Introduction 
Behçet’s disease is a chronic multisystemic vasculitis affecting small and large arterial and 
venous branches (Yazici et al, 2010). The condition presents a distinctive geographical 
pattern, with higher incidence rates in Turkey, other Mediterranean countries and Middle 
and Far East countries, following the ancient “silk route” until Japan. On the other hand, it is 
rare in Northern Europe and United States. Genetic and environmental factors have been 
proposed as responsible for this unique distribution, but not fully explaining those 
differences (Verity et al, 1999). HLA-B51 is the strongest genetic association, but only 
explains 20% of disease heritability and Japanese patients with Behçet’s disease do not share 
this association. An environmental trigger might play a role on the onset of the disease; this 
is suggested by the fact that the incidence rate of Behçet’s disease in Turkish people living in 
Germany is considerably lower compared to those living in Turkey (Zouboulis et al, 1997). 
Though mucocutaneous features are the most frequent clinical involvement in Behçet’s 
disease, some patients suffers from severe eye involvement (chronic posterior uveitis), 
arterial aneurisms and central nervous system disease, leading to significant morbidity and 
mortality. Male and young patients often have a more severe disease. Management is 
mainly symptomatic and empiric. Drugs commonly used are topical and systemic 
glucocorticoids, colchicine, azathioprine or thalidomide. Severe cases may require 
cyclosporin, cyclophosphamide and high doses of glucocorticoids. Functional visual loss 
due to Behçet’s disease uveitis is seen in 10-15% of patients. Mortality of pulmonary artery 
aneurisms is about 50%. Central nervous system is associated to 30% rate of mortality 
(Saadoun et al, 2010). So despite the usual schemes of management, there is ongoing 
morbidity and mortality in patients with Behçet’s disease. Further more effective and less 
harmful agents are awaited, and biological agents might be this desired option; efficacy and 
safety data will be reviewed in this section. 
4.2 TNF blockade 
Tumour necrosis factor (TNF) inhibitors are the most widely used biological agents in 
Behçet’s disease. Beside clinical, there are experimental data supporting this use: First, 
Behçet’s disease was found to be mediated by cytokines derived from Th1 lymphocytes, 
including TNF (Gul, 2001). Second, patients with active disease showed an increased TNF 
expression (Yamashita et al, 1997; Mege et al, 1993). And third, TNF levels, both in sera and 
in aqueous humour, are increased in Behçet’s disease (Evereklioglu et al, 2002; 
Chronopoulou et al, 2001). 
Anti-TNF agents have been essentially tried in patients with refractory features of the 
disease. Case reports and retrospective case series were the initial data, but later prospective 
controlled studies have been reported. Generally, anti-TNF agents are recommended for 
patients with active disease which is refractory to conventional treatments (Sfikakis et al, 
2007). But evidence level is not equal for each Behçet’s feature, so we will separately review 
the most common or troublesome manifestations of the disease, regarding data about 
efficacy and safety of the anti-TNF agents. 
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4.2.1 Mucocutaneous and joint disease 
The mainstay manifestation of Behçet’s disease is the recurrent oral ulceration. It is the usual 
onset feature, is present in virtually all patients and is the required criteria for the diagnosis 
of the disease (International Study Group for Behçet's Disease, 1990). Other skin 
manifestations are genital ulcers (scrotum, major and minor labia), papulo-pustular acne-
like lesions, subcutaneous nodules in lower limbs (remedying those of erythema nodosum), 
skin ulcers, pyoderma gangrenosum or palpable purpura. Oral and genital ulcers are 
typically mildly painful and completely heal after 1-3 weeks, but larger ones can leave a 
scar. The management usually includes topical glucorticoids, colchicine or thalidomide. 
Patients with Behçet’s disease often present with arthritis, typically simetrical or asimetrical 
non-erosive oligoarthitis. Commonly affects to knees, wrists, ankles or elbows. Sometimes 
arthritis develops in a monoarticular or polyarticular pattern. Erosive arthritis is rare and 
later studies have found no association with axial involvement.  
Skin and joint involvement is often mild and easily controlled. But these features might be 
very distressing with a significant physical and psychological burden. Occasionally some 
patients present with a persistent and severe condition, refractory to conventional 
treatments. There are some reports about using anti-TNF drugs in this small group of 
patients. In 2001, first case reports were published. Goossens et al reported a patient with 
mouth, anous, praeputium and left foot ulcers, refractory to conventional treatment, who 
achieved a sustained remission after two infusions of infliximab 10mg/kg. A 65 year-old 
woman, with history of 10 years of persistent orogenital ulcers despite several treatments 
(glucocorticoids, colchicine, thalidomide, azathioprine, cyclosporin and dapsone), 
successfully responded to infliximab (5mg/kg) three infusions (0, 2 and 6 weeks) (Robertson 
& Hickling, 2001). Others cases of refractory Behçet’s skin involvement controlled with anti-
TNF have been reported (Haugeberg et al, 2004; Almoznino & Ben-Chetrit, 2007). 
In 2005, a double-blind, placebo-controlled trial evaluating etanercept in Behçet’s disease 
was published (Melikoglu et al, 2005). The aim of the authors was to evaluate the effect of 
etanercept in pathergy and monosodium urate (MSU) reactions, and in minor Behçet’s 
features (patients with severe manifestations were excluded). Pathergy reaction consists in 
the development of a papule or pustule 48 hours after an intradermal needle prick. MSU 
reaction is the persistence of erythema 48 hours after an intradermal inoculation of MSU 
crystals. Both reactions demonstrate skin hypersensitivity and are high specific for Behçet’s 
disease (Gilhar et al, 1989). Enrolled patients randomised to receive etanercept (25mg twice 
a week) or placebo. After 4 weeks of treatment and 3 months of follow-up, patients in 
etanercept showed lower rates of oral ulcers, subcutaneous nodules and papulo-pustular 
lesions, but differences disappeared after discontinuation of the drug. Inflammatory 
markers also decreased. Genital ulcers and arthritis showed no benefits with etanercept. 
Interestingly, no effect on pathergy and MSU reaction was found. Treatment was safe and 
well-tolerated, with no significant adverse events. Despite some bias (small size, short-term 
follow-up, etc.), this was the first and successful controlled study with anti-TNF drugs in 
Behçet’s disease, focused on its skin and joint manifestations. 
4.2.2 Eye disease 
More than 50% of patients with Behçet’s disease will present with eye involvement (Yacici et 
al, 2010). This may occur at every point on the course of the disease, but in male and 
younger patients tends to develop in first 3 years after diagnosis, leading to a worse 
prognosis. Behçet’s eye disease is a chronic, relapsing bilateral non-granulomatous 
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panuveitis, affecting both anterior and posterior poles of the ocular globe. Retinal occlusive 
vasculitis is often seen; conjunctivitis is rare. The disease runs with recurrent severe attacks, 
followed by spontaneous remissions. Though not associated to mortality, uveitis is one of 
the leading causes of morbidity in Behçet’s disease. About 20-30 years ago the rate of 
blindness due to uveitis was higher than 75% of patients. Fortunately, better schemes of 
management and higher level of awareness made this outcome decrease, but still 10-15% of 
patients will develop functional visual loss (Kural-Seyahi et al, 2003). Loss of sight is due to 
permanent damage of intraocular structures by recurrent inflammatory attacks, atrophy of 
the optic nerve, secondary glaucoma or cataracts. 
The management of patients with Behçet’s eye disease should achieve rapid resolution of 
intraocular inflammation, prevent further attacks and preserve vision. Rapid control of 
inflammation is highly imperative in acute posterior uveitis (anterior pole inflammation 
usually is not severe and is well controlled with topical treatment). Glucocorticoids, 
azathioprine and cyclosporin are generally used, even in combination for refractory cases. 
However, despite these drugs, some patients will persist with recurrent flares leading to 
visual loss. In this subgroup of patients, monoclonal anti-TNF agent infliximab showed 
promising results in single reports and case series. In five patients with recurrent panuveitis, 
a single infusion of infliximab achieved a rapid remission in 24 hours and complete 
resolution in following 7 days (Sfikakis et al, 2001). Muñoz-Fernandez et al (2001) reported a 
successful outcome with infliximab 5mg/kg on a patient with sight-threatening panuveitis: 
inflammatory signs resolved and visual acuity significantly improved after three infusions. 
Another patient with severe neuroretinitis, oral and genital ulcers, arthritis, erythema 
nodosum and superficial thrombophlebitis, was treated with infliximab 5mg/kg at 0, 2, 4 
and 8 weeks scheme. All symptoms significantly improved after first infusion, achieving 
remission with the second one (Triolo et al, 2002). 
In 2005, a prospective evaluation of infliximab in Behçet’s uveitis was published (Tugal-
Tutkun et al, 2005). Thirteen male patients with recurrent posterior uveitis refractory to 
combination of cyclosporin, azathioprine and prednisolone were enrolled. Cyclosporin was 
discontinued. The authors used infliximab at 5mg/kg dose, administered at weeks 0, 2, 6 
and 14 weeks. During the infusion period, lower incidence of eye flares were noted 
compared to pre-enrolment period, achieving 4 of them (30.8%) remission. No extraocular 
features of the disease occurred during this period and prednisolone dose reduced. 
Interestingly, the effect of infliximab got lost in the observation period (between weeks 23 
and 54): there was no significant difference with the previous-treatment, and only 1 patient 
remained attack-free. Safety profile was acceptable, with no severe events. Since then, other 
prospective uncontrolled trials have been reported. Tognon et al (2007) tried infliximab in 7 
patients with sight-threating uveitis refractory to several immunosuppressive agents, with 
excellent results: intensity and number of relapses decreased, and visual acuity improved in 
30% of eyes while in the rest remained stable. Extraocular manifestation controlled as well. 
No safety problems were noted. Niccoli et al (2007) assessed the efficacy of infliximab 
5mg/kg (9 infusions) plus prednisolone 1mg/kg over a long-term follow-up (24 months) in 
12 consecutive patients with refractory posterior uveitis. A rapid response was noted after 
first infusion. At 12 months, 75% of the patients achieved a complete remission with no 
relapses detected, and at 24 months 78% of them still remained in remission. Treatment was 
well tolerated with no significant adverse events.  
There are no prospective controlled trials evaluating infliximab in Behçet’s uveitis. But two 
reports retrospectively evaluated infliximab against conventional immunosuppressive 
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therapy (Tabbara & Al-Hemidan, 2008; Yamada et al, 2010). Both studies showed excellent 
results in the group of patients treated with infliximab, with significantly lower number of 
acute flares. Visual acuity improved in both groups, but only in the study by Tabbara 
median values were significantly higher with infliximab. It is noteworthy that more severe 
adverse events were noted in patients treated with conventional agents. An arguable bias 
for these studies is that treatment groups are not comparable – patients treated with 
infliximab present a more aggressive uveitis, refractory to high immunosuppression; but the 
fact that infliximab succeed, even better than previous agents, is an encouraging data. 
Infliximab is nowadays recommended for acute flares of posterior uveitis with significant 
reduction of visual acuity; when remission is achieved, infliximab may be switched to 
immunosuppressive drugs, as cyclosporin or azathioprine, with low-dose oral 
glucocorticoids (Sfikakis et al, 2007). As known from rheumatoid arthritis, long-term use of 
infliximab may lead to the development of resistances (Ito el al, 2010), as it is a chimeric, not 
fully humanised monoclonal antibody. 
Evidence of efficacy with etanercept in Behçet’s eye disease is lacking – there are scant 
reports and, as previously commented, in controlled trial by Melikoglu (2005) patients with 
active eye disease were not enrolled - so this drug cannot be recommended. Adalimumab 
seems to be effective in refractory Behçet’s uveitis, but data only come from case reports and 
retrospective series (Mushtaq et al, 2007; Bawazeer & Raffa, 2010; Takase K et al, 2011), so 
further research is needed. 
4.2.3 Gastrointestinal disease 
Gastrointestinal involvement is one of the most frequent features in patients with Behçet’s 
disease from Japan, Taiwan and Northern Europe – ranges from 30% to 50% - while the 
frequency in Turkey and Western Asia is low – about 5% (Ebert, 2009; Yacizi et al, 2010). 
Beside mouth ulcers, Behçet’s disease predominantly affects small and large bowel, 
especially around ileocecal region. Esophageal, gastric or rectal involvement is rare. Type of 
intestinal involvement depends on subjacent vasculitis: small vessel vasculitis leads to 
mucosal inflammation and aphthous ulcers, meanwhile large vessel vasculitis associates 
with ischemia and infarction. Abdominal pain is the most common complaint; others are 
bloody stools, persistent diarrhoea or unexplained weight loss. The disease is often mild, but 
some patients complicates with perforation, mesenteric ischemia or major gastrointestinal 
bleeding. Gastrointestinal involvement typically associates with cutaneous papulo-pustular 
lesions and pyoderma gangrenosum. 
As well as other Behçet’s features, intestinal disease runs in an unpredictable course with 
flares and remissions. Recurrences after treatment are frequent, even after surgery, 
especially on the anastomotic site (Ha HK et al, 1998). In two case series from France 
(Saadoun et al, 2010) and Turkey (Kural-Seyahi et al, 2003) no patients died due to intestinal 
involvement, but in French series pancreatitis was the cause of death in one patient. Behçet’s 
bowel disease management is similar to other features of the condition, where 
glucocorticoids and colchicine for mild disease and azathioprine or cyclosporin for severe 
disease are commonly used. Thalidomide and mesalazine could act as glucocorticoids-dose 
sparing agents. Anti-TNF agents have been used, but data mainly come from case reports 
(Hassard et al, 2001). Iwata et al (2009) tried infliximab in 10 patients with active entero-
Behçet’s disease refractory to conventional immunosuppressive agents or with 
contraindications against its use. All patients showed a rapid improvement in the intestinal 
manifestations, achieving remission 5 out 10 patients at 6 months, and 9 out 10 at 12 months. 
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Extraintestinal features of the disease improved as well and no severe adverse events were 
detected. Infliximab was used at dosage of 3mg/kg, but one patient required an increase to 
5mg/kg due to a suspected recurrence. In another case series (Naganuma et al, 2008) 6 
patients with fulminant intestinal disease were treated with infliximab with successful 
outcome, getting 5 of the six patients on remission. Despite limitation by lacking of 
controlled trials, current evidence supports the use of infliximab in refractory, severe cases 
of Behçet’s intestinal disease. There is no data about etanercept or adalimumab, so formal 
recommendations cannot be done. 
4.2.4 Central nervous system disease 
Neurological involvement in Behçet’s disease widely ranges between series, from 1.3% to 
59%, with an average of about 10% of patients (Al-Araji & Kidd, 2009), usually developing a 
few years after the diagnosis of the disease. Men have two-three times higher risk of 
development compared to women. The condition specifically affects to central nervous 
system (CNS); peripheral involvement is uncertain. Though infrequent, it is often included 
in differential diagnosis in demyelinating and inflammatory CNS disorders. CNS-Behçet’s 
disease presents with two different forms, rarely both in a same patient. First, parenchymal 
CNS disease is a subacute meningoencephalitis mainly located to brainstem, basal ganglia, 
thalamus and white matter. Hemispheres, spinal cord and other parts of CNS might be 
affected as well, but more common as a diffuse rather than focal involvement. And second, 
vessels, especially veins, are affected in non-parenchymal CNS-Behçet’s disease, leading to 
cranial venous thrombosis and intracranial hypertension. Strokes due to arterial 
involvement are seldom seen. Patients complain of nonspecific symptoms (headache, 
malaise, fatigue, fever, etc.) and signs and symptoms derived from the area of CNS affected. 
A silent form has been described in asymptomatic patients but with detectable signs on the 
neurological examination. 
Neuro-Behçet’s disease is one of the most serious causes of morbidity and mortality in 
Behçet’s. In spite of around a third of patients will present single episodes, another third will 
suffer further relapses and the other third a persistent, progressive involvement with 
aggravating neurological function (Akman-Demir et al, 1999). And how rapid the treatment 
is initiated probably will influence in further prognosis. Prospective controlled trials in 
Neuro-Behçet’s disease are lacking, so treatment schemes are largely empirical. Intravenous 
methylprednisolone, followed by tapering prednisolone, is the first line agent after 
diagnosis. Initiation of an immunosuppressive agent (i.e. azathioprine, methotrexate or 
mycophenolate mofetil) depends on severity, previous episodes and response to 
glucocorticoids. 
As well as in other less common Behçet’s features, no adequate controlled studies have 
evaluated the role of anti-TNF agents in neuro-Behçet’s. But results from case series are very 
promising. Pipitone et al (2008) retrospectively reviewed 8 patients with parenchymal 
neuro-Behçet’s disease treated with infliximab. Dosage of 5 mg/kg was used in all patients, 
and adjunct drugs varied. Neurological involvement was refractory to immunosuppressive 
agents or developed while this treatment was being used due to other features of the 
disease. All 8 patients successfully responded to treatment, with rapid and marked 
improvement of symptoms. In one patient infliximab lost his efficacy after 5 years, with 
recurrence of symptoms, but improved again after initiating etanercept. No safety problems 
were reported. Other series (Kikuchi et al, 2008) also showed good results with infliximab 
5mg/kg in 5 patients with progressive neuro-Behçet’s disease refractory to glucocorticoids 
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and methotrexate. Infliximab was added to former treatment scheme. Interestingly, the 
authors found marked reduction of interleukin-6 levels on cerebrospinal fluid after initiating 
the drug, meanwhile TNF levels remained unchanged. One patient developed a suspected 
Pneumocystis jiroveci pneumonia during the treatment, responding to cotrimoxazole. In 
summary, further controlled trials are highly desirable, but we consider that anti-TNF 
agents should be tried in cases with refractory neurological Behçet’s disease. 
4.2.5 Vascular disease 
Vascular involvement in Behçet’s disease affects venous and arterial systems, both with an 
inflammatory basis (Yacizi et al, 2010). Approximately, one third of patients will present 
venous thrombosis on deep or superficial systems, typically on their lower limbs. 
Interestingly, pulmonary embolisms are very rare. Venous thrombosis can develop in other 
body locations, as suprahepatic veins - leading to Budd-Chiari syndrome (Seyahi et al, 2007) 
- or intracranial venous sinuses, as previously commented. Arterial involvement is lees 
frequent (<5%), but associated with poorer outcomes. Inflammatory pseudoaneurisms form 
in abdominal aorta, carotid, femoral or pulmonary arteries. If left untreated, mortality of 
pulmonary artery aneurisms is about 50% (Hamuryudan et al, 1994). Due to the 
inflammatory basis and the very low rate of embolism, not anticoagulation but 
immunosuppression is the mainstay of the management of Behçet’s vascular disease, 
though controlled studies are lacking. Glucocorticoids and azathioprine or methotrexate 
may be used for venous thrombosis, but arterial involvement requires high-dose 
endovenous methylprednisolone and cyclophosphamide. The experience with anti-TNF 
agents lies on reported cases of refractory, life-threatening vascular involvement (Lee et al, 
2010; Baki et al, 2006), with successful outcomes. No increased risk of atherosclerosis has 
been found in Behçet’s disease. 
4.3 Other biological agents 
Rituximab, a chimeric monoclonal antibody against CD20 surface marker of B-cells, is 
widely used in other systemic autoimmune disorders, as rheumatoid arthritis, systemic 
lupus erythematosus or ANCA-associated vasculitis. Rituximab has been used in Behçet’s 
disease as well. In 2008, Sadreddini et al communicated a patient with a severe retinal 
vasculitis refractory to azathioprine who developed hypersensitivity to etanercept. In this 
patient, rituximab (1gr, 2 infusions 2 weeks apart) improved the inflammatory signs and 
visual acuity in 6 weeks after the infusion. Recently, a pilot study evaluating rituximab in 
Behçet’s eye disease has been published (Davatchi et al, 2010). Twenty patients with Behçet’s 
uveitis and partial or absent response to cytotoxic agents were enrolled and randomised to 
receive rituximab (1gr, 2 infusions 2 weeks apart, plus weekly methotrexate and oral 
prednisolone) or an aggressive cytotoxic regime with cyclophosphamide, azathioprine and 
oral prednisolone. The author used the change in Total Adjusted Disease Activity Index 
(TADAI), a combination of different parameters of eye examination, as an outcome measure. 
TADAI and every single measure improved in both groups, but the difference between 
groups was no significant. Serious adverse events were detected in rituximab group – 
pneumonia in one patient and a severe infusion reaction in another. Though rituximab was 
as effective as cytotoxic schemes in Behçet’s uveitis, further studies are needed.  
As well as TNFinterleukin and other pro-inflammatory cytokines levels are elevated 
in sera of patients with active Behçet's disease (Duzgun et al, 2005). Furthermore, an increase 
in interleukin-1 receptor antagonist, one of the natural immunomodulating molecules of this 
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cytokine, has been reported after controlling the disease (Benezra et al, 1997). In our search, 
we found an only report about using interleukin-1 antagonist anakinra in patients with 
Behçet's disease: Botsios et al [2008] communicated an excellent response to anakinra in a 75 
year-old woman whose disease was previously refractory to several immunosuppressive 
agents and partially responded to infliximab. Further studies are clearly needed to establish 
formal recommendations. 
The anti-interleukin 2 receptor CD25 monoclonal antibody daclizumab was tested in a 
prospective placebo-controlled trial in Behçet’s uveitis (Buggage et al, 2007). Patients in both 
groups continued to receive their previous immunosuppressive agents, and endovenous 
infusions of daclizumab 1mg/kg or placebo was added every two weeks for six weeks (4-
dose induction), then once every four weeks for a minimum of 24 months following 
randomization. Ocular attacks continued to happen in both groups, but rate was even 
higher in patients on daclizumab arm. No safety problems were reported. Daclizumab is not 
recommended for the management of Behçet’s disease. 
Auto-reactive T lymphocytes may have a role in pathogenesis of Behçet's disease, explaining 
the successful response to calcineurin inhibitors (as cyclosporin) seen in this disease. In 2003, 
a series with patients with Behçet's disease treated with the anti-CD52 humanised 
monoclonal antibody alemtuzumab (CAMPATH-1H) was published (Lockwood et al, 2003). 
Patients with different active disease features were enrolled, being thirteen of them 
refractory to immunosuppressive agents. After a course of 5 daily infusions of alemtuzumab 
(total 134mg), eight patients achieved complete remission and seven patients showed a 
partial remission after 3 months of follow-up. Seven patients required further 
immunosuppressive agents to control the disease. No serious adverse events were detected. 
No controlled group was used in this study, but T-cells might be a new promising target for 
the management of Behçet's disease. 
5. Mixed cryoglobulinemic vasculitis 
Mixed cryoglobulinemic vasculitis (MC) is a small-vessel vasculitis characterised by the 
proliferation of B-cell clones producing pathogenic IgM with rheumatoid factor activity. 
More than 80% of MC vasculitis cases are attributable to hepatitis C viral (HCV) infection. 
Patients whose manifestations are not controlled by standard therapy, could be candidates 
for new biological therapy.  
Rituximab is a chimeric murine/human anti-CD20 monoclonal antibody that binds to the B 
cell surface antigen CD20, resulting in selective depletion of peripheral B cells which can last 
for 6 months or longer.  In order to analyse the efficacy and tolerance of rituximab treatment 
in patients with MC vasculitis, Cacoub et al performed a systematic review (Cacoub et al., 
2008), which founded 13 manuscripts that reported on a total number of 57 cases of MC 
secondary to hepatitis C virus (HCV) infection (43 patients, 75.4%) or essential mixed 
cryoglobulinemia (14 patients, 24.6%). There were two large uncontrolled series of 20 
(Sansonno et al, 2003) and 15 (Zaja et al, 2003) patients, and two smaller series of 6 
(Roccatello et al, 2004) and 5 (Quartuccio et al, 2006) patients. All other publications reported 
either single or two case reports. Most patients (48 out of 57) received four weekly 
consecutive intravenous infusions of 375 mg/m2 of rituximab for either unresponsiveness 
or intolerance to previous treatments (n=52). The duration of follow-up after rituximab 
therapy was 9.7 months. Partial or complete remissions were observed in 80% of patients 
with skin involvement, 79% of patients with arthralgias, 93% of patients with neuropathy, 
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and 83%of patients with glomerulonephritis. A relapse of MC was noted in 14 out of 36 
(39%) patients after a mean of 6.7 months; eight of these patients went into complete 
remission after a second course of rituximab. A relatively small number of side effects were 
reported. The authors concluded that rituximab therapy for patients with MC vasculitis, 
either HCV induced or essential, shows a great efficacy on the main vasculitis signs in the 
majority of reported patients. A relapse of cryoglobulinemia vasculitis was frequently noted.  
About 30% of MC patients undergo active disease despite treatment with rituximab or 
antiviral therapy alone. So the combination of rituximab with Peg-IFNα-ribavirin appears 
logical. The long-term follow-up of a cohort of patients with HCV–related vasculitis treated 
with rituximab with or without PEGylated interferon alfa-2b (PEG–IFN alfa-2b) plus 
ribavirin has been reported (Terrier et al., 2009). Patients received rituximab 375 mg/m2 and 
40mg of intravenous methylprednisolone weekly for 4 weeks, followed by 1 year of therapy 
with PEG–IFN alfa-2b and ribavirin. The study group comprised 32 HCV RNA–positive 
patients with HCV-related vasculitis: 20 patients were treated with rituximab plus PEG–IFN 
alfa-2b and 12 antiviral-intolerant patients were treated with rituximab alone. Of the 20 
patients with combined-treatment, 9 had not previously received antiviral treatment, while 
11 were resistant to or had relapsed after combination antiviral therapy: all of them were 
previously enrolled in a 16-patient study (Saadoun et al, 2008), the 5 remaining patients in 
that study died - 1 patient - or were lost to follow-up - four patients. Complete remission 
was achieved in 80% of patients with combined-treatment, and partial remission in 15% of 
cases. A complete or partial immunologic response was observed in 67 and 33% of patients, 
respectively. The 12 patients who received rituximab alone because of intolerance of 
antiviral treatments experience complete or partial clinical response in 58 and 9% of patients 
respectively. Relapses were recorded in 22% of patients after a mean follow-up period of 
23±12 months and these relapses were associated with loss of virologic control in all patients 
and with B cell recovery in 78% of cases. 
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